The Week

Alpha Tau Medical (DRTS) closed the week down 3.99% at $14.43, underperforming the S&P 500’s 0.80% decline by about 3.19 percentage points. The week opened firm on Tuesday (Sep 8), peaking at $15.08, before sliding to a weekly low of $13.80 on Thursday (Sep 10). Friday (Sep 11) was choppy and finished near the prior close at $14.43. Weekly amplitude was 8.52%, with average daily volume of 460.6k shares, around 19% below the 60-day median. With no major announcements or results out this week, the move mostly tracked broader market sentiment.

Analyst Ratings

Coverage is thin. Five brokers rate the stock: three buy, one overweight, one hold, and none underweight or sell. The consensus rating is buy. The consensus target price sits at $17.80, about 23.35% above the latest price of $14.43. Targets are widely spread, from $8.00 at the low end to $30.00 at the high end, signalling a meaningful gap in views. Within medical devices, its industry rating rank is 62 out of 142.

The Week Ahead

A run of US macro data lands next week: the Empire State manufacturing index on Tuesday (Sep 15), followed by retail sales and import prices on Wednesday (Sep 16). DRTS has no scheduled results of its own, so near-term price action will likely hinge on the broader tape and sector risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.